Arrowhead: How an RNAi Bet Becomes a Platform Player

With REDEMPLO, $829 million in revenue, and nearly reaching profitability, Arrowhead makes the leap from a lab stock to an operational biotech story. The TRiM platform targets up to seven tissue types and opens the door to a whole portfolio of potential RNAi drugs well beyond the rare FCS indication. Arrowhead Pharmaceuticals from Pasadena is one of those biotech stories where a technological promise suddenly becomes visible in numbers. In 2025, it made the leap to a commercial company: With REDEMPLO, the first drug based on its own TRiM...